exosurf neonatal powder for suspension
glaxosmithkline inc - colfosceril palmitate - powder for suspension - 108mg - colfosceril palmitate 108mg - miscellaneous therapeutic agents
exosurf neonatal powder for suspension
glaxosmithkline inc - colfosceril palmitate - powder for suspension - 108mg - colfosceril palmitate 108mg - miscellaneous therapeutic agents
exosurf neonatal
glaxosmithkline nz limited - colfosceril palmitate 108mg - powder for intratracheal suspension - 108 mg - active: colfosceril palmitate 108mg
exosurf neonatal 67.5mg endotracheal powder vials and diluent
glaxosmithkline uk ltd - colfosceril palmitate - powder for suspension for endotracheopulmonary instillation - 67.5mg
exosurf neonatal 108mg endotracheal powder vials and diluent
glaxosmithkline uk ltd - colfosceril palmitate - powder for suspension for endotracheopulmonary instillation - 108mg
survanta
abbvie limited - bovine lung lipids 25 mg/ml (total phospholipids); colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine); palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid); tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) - intratracheal suspension - 25 mg/ml - active: bovine lung lipids 25 mg/ml (total phospholipids) colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine) palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid) tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) excipient: sodium chloride water for injection - survanta is indicated for prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. survanta significantly reduces the incidence of rds, mortality due to rds and air leak complications.
survanta beractant (as phospholipids) 200mg/8ml suspension vial
abbvie pty ltd - beractant, quantity: 25 mg/ml - suspension - excipient ingredients: colfosceril palmitate; tripalmitin; palmitic acid; sodium chloride; phosphatidyl choline; water for injections - prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants.
exosurf neonatal
wellcome (ireland) limited - colfosceril palmitate - pdr+solv/susp/epulminst - 13.5 mg/ml
survanta
abbvie pty ltd - beractant -
definity
global medical solutions (nz) limited - perflutren 1.1 mg/ml - solution for injection - 1.1 mg/ml - active: perflutren 1.1 mg/ml excipient: colfosceril palmitate dibasic sodium phosphate monohydrate glycerol sodium dipalmitoylphosphatidate n-(methoxy-peg-5000 carbamoyl)-dipalmitoylphosphatidylethanolamine sodium monobasic sodium phosphate monohydrate propylene glycol sodium chloride water for injection